Autopsy report · NCT01290328

Study of Epoetin Alfa to Treat Anemia After Kidney Transplantation

“low enrollment, termination of funding”

The sponsor’s own words in the registry.

Life of this trial

• Ran for about 3 years 2 months before it stopped.
• 100 participants planned (an estimate, not an actual count).
• No results are posted on the registry.

Vital statistics

Status

Terminated

Phase

Na

Sponsor

Mehrotra, Anita, M.D.

Sponsor type

University, hospital or other

Conditions

Anemia

Interventions

Epoetin Alfa

Participants

100 (planned, not actual)

Sites

1

Countries

United States

Trials that died the same way

• ALgorithms Adapted From Remote Monitoring
  “Low enrollment, completion of funding” (89% match in meaning)
• Clinical Trial of Nebulized Hypertonic Saline to Attenuate Post-Traumatic Acute Lung Injury
  “low enrollment and loss of funding” (88% match in meaning)
• Evaluate The Effectiveness Of Fospropofol (Lusedra®) For Induction Of Anesthesia
  “Loss of funding before enrollment.” (85% match in meaning)
• Extracorporeal CO2 Removal for Acute Decompensation of COPD
  “Lack of enrollment, termination of funding.” (82% match in meaning)
• Ridaforolimus With Cetuximab: Adv Non-Small Cell Lung, Colorectal, Head & Neck Cancer
  “Determination to stop enrollment made due to funding” (82% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.